SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer

Trends in Biochemical Sciences

Volumn 40, Issue 12, 2015, Pages 779-793

  Eifler, Karolin ^a   Vertegaal, Alfred C O ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Cell cycle; Mitosis; SUMO; SUMOylation

Indexed keywords

CYCLIN DEPENDENT KINASE; SUMO PROTEIN; UBIQUITIN;

CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CHROMOSOME; DISEASE ACTIVITY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MITOSIS; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; ANIMAL; CELL CYCLE; DISEASE COURSE; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; CELL CYCLE; DISEASE PROGRESSION; HUMANS; NEOPLASMS; SUMOYLATION;

EID: 84951036401     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2015.09.006     Document Type: Review

References (144)

1. Johnson L.N. The regulation of protein phosphorylation. Biochem. Soc. Trans. 2009, 37:627-641.
2. Moremen K.W., et al. Vertebrate protein glycosylation: diversity, synthesis and function. Nat. Rev. Mol. Cell Biol. 2012, 13:448-462.
3. Choudhary C., et al. The growing landscape of lysine acetylation links metabolism and cell signalling. Nat. Rev. Mol. Cell Biol. 2014, 15:536-550.
4. Goldstein G., et al. Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc. Natl. Acad. Sci. U.S.A. 1975, 72:11-15.
5. Soucy T.A., et al. The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 2010, 1:708-716.
6. Zhao C., et al. Interferon-induced ISG15 pathway: an ongoing virus-host battle. Trends Microbiol. 2013, 21:181-186.
7. Hipp M.S., et al. FAT10, a ubiquitin-independent signal for proteasomal degradation. Mol. Cell Biol. 2005, 25:3483-3491.
8. Basler M., et al. The ubiquitin-like modifier FAT10 in antigen processing and antimicrobial defense. Mol. Immunol. 2015, Published online May 13, 2015. 10.1016/j.molimm.2015.04.012.
9. Muller S., et al. SUMO: a regulator of gene expression and genome integrity. Oncogene 2004, 23:1998-2008.
10. Jackson S.P., Durocher D. Regulation of DNA damage responses by ubiquitin and SUMO. Mol. Cell 2013, 49:795-807.
11. Melchior F., et al. SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem. Sci. 2003, 28:612-618.
12. Seufert W., et al. Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins. Nature 1995, 373:78-81.
13. Dieckhoff P., et al. Smt3/SUMO and Ubc9 are required for efficient APC/C-mediated proteolysis in budding yeast. Mol. Microbiol. 2004, 51:1375-1387.
14. Johnson E.S., et al. The ubiquitin-like protein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer. EMBO J. 1997, 16:5509-5519.
15. Dohmen R.J., et al. An essential yeast gene encoding a homolog of ubiquitin-activating enzyme. J. Biol. Chem. 1995, 270:18099-18109.
16. Johnson E.S., Blobel G. Cell cycle-regulated attachment of the ubiquitin-related protein SUMO to the yeast septins. J. Cell Biol. 1999, 147:981-994.
17. Nacerddine K., et al. The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev. Cell 2005, 9:769-779.
18. Wang L., et al. SUMO2 is essential while SUMO3 is dispensable for mouse embryonic development. EMBO Rep. 2014, 15:878-885.
19. Evdokimov E., et al. Loss of SUMO1 in mice affects RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be compensated by SUMO2 or SUMO3. J. Cell Sci. 2008, 121:4106-4113.
20. Zhang F.P., et al. Sumo-1 function is dispensable in normal mouse development. Mol. Cell. Biol. 2008, 28:5381-5390.
21. Hayashi T., et al. Ubc9 is essential for viability of higher eukaryotic cells. Exp. Cell Res. 2002, 280:212-221.
22. Neyret-Kahn H., et al. Sumoylation at chromatin governs coordinated repression of a transcriptional program essential for cell growth and proliferation. Genome Res. 2013, 23:1563-1579.
23. Schimmel J., et al. Uncovering sumoylation dynamics during cell-cycle progression reveals FoxM1 as a key mitotic SUMO target protein. Mol. Cell 2014, 53:1053-1066.
24. Ayaydin F., Dasso M. Distinct in vivo dynamics of vertebrate SUMO paralogues. Mol. Biol. Cell 2004, 15:5208-5218.
25. Brown P.W., et al. Small ubiquitin-related modifier (SUMO)-1, SUMO-2/3 and SUMOylation are involved with centromeric heterochromatin of chromosomes 9 and 1 and proteins of the synaptonemal complex during meiosis in men. Hum. Reprod. 2008, 23:2850-2857.
26. Vigodner M. Sumoylation precedes accumulation of phosphorylated H2AX on sex chromosomes during their meiotic inactivation. Chromosome Res. 2009, 17:37-45.
27. Pelisch F., et al. Dynamic SUMO modification regulates mitotic chromosome assembly and cell cycle progression in Caenorhabditis elegans. Nat. Commun. 2014, 5:5485.
28. Azuma Y., et al. PIASy mediates SUMO-2 conjugation of Topoisomerase-II on mitotic chromosomes. EMBO J. 2005, 24:2172-2182.
29. Joseph J., et al. SUMO-1 targets RanGAP1 to kinetochores and mitotic spindles. J. Cell Biol. 2002, 156:595-602.
30. Joseph J., et al. The RanGAP1-RanBP2 complex is essential for microtubule-kinetochore interactions in vivo. Curr. Biol. 2004, 14:611-617.
31. Dawlaty M.M., et al. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha. Cell 2008, 133:103-115.
32. Hang J., Dasso M. Association of the human SUMO-1 protease SENP2 with the nuclear pore. J. Biol. Chem. 2002, 277:19961-19966.
33. Cubenas-Potts C., et al. SENP1 and SENP2 affect spatial and temporal control of sumoylation in mitosis. Mol. Biol. Cell 2013, 24:3483-3495.
34. Zhang X.D., et al. SUMO-2/3 modification and binding regulate the association of CENP-E with kinetochores and progression through mitosis. Mol. Cell 2008, 29:729-741.
35. Kolli N., et al. Distribution and paralogue specificity of mammalian deSUMOylating enzymes. Biochem. J. 2010, 430:335-344.
36. Garvin A.J., et al. The deSUMOylase SENP7 promotes chromatin relaxation for homologous recombination DNA repair. EMBO Rep. 2013, 14:975-983.
37. Goeres J., et al. The SUMO-specific isopeptidase SENP2 associates dynamically with nuclear pore complexes through interactions with karyopherins and the Nup107-160 nucleoporin subcomplex. Mol. Biol. Cell 2011, 22:4868-4882.
38. Maison C., et al. The SUMO protease SENP7 is a critical component to ensure HP1 enrichment at pericentric heterochromatin. Nat. Struct. Mol. Biol. 2012, 19:458-460.
39. Romeo K., et al. The SENP7 SUMO-protease presents a module of two HP1 interaction motifs that locks HP1 protein at pericentric heterochromatin. Cell Rep. 2015, 10:771-782.
40. Zunino R., et al. Translocation of SenP5 from the nucleoli to the mitochondria modulates DRP1-dependent fission during mitosis. J. Biol. Chem. 2009, 284:17783-17795.
41. Di Bacco A., et al. The SUMO-specific protease SENP5 is required for cell division. Mol. Cell Biol. 2006, 26:4489-4498.
42. Klein U.R., et al. RanBP2 and SENP3 function in a mitotic SUMO2/3 conjugation-deconjugation cycle on Borealin. Mol. Biol. Cell 2009, 20:410-418.
43. Hietakangas V., et al. PDSM, a motif for phosphorylation-dependent SUMO modification. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:45-50.
44. Mohideen F., et al. A molecular basis for phosphorylation-dependent SUMO conjugation by the E2 UBC9. Nat. Struct. Mol. Biol. 2009, 16:945-952.
45. Asghar U., et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov. 2015, 14:130-146.
46. Henneke G., et al. Phosphorylation of human Fen1 by cyclin-dependent kinase modulates its role in replication fork regulation. Oncogene 2003, 22:4301-4313.
47. Guo Z., et al. Sequential posttranslational modifications program FEN1 degradation during cell-cycle progression. Mol. Cell 2012, 47:444-456.
48. Hendriks I.A., et al. Uncovering global SUMOylation signaling networks in a site-specific manner. Nat. Struct. Mol. Biol. 2014, 21:927-936.
49. Hendriks I.A., et al. System-wide identification of wild-type SUMO-2 conjugation sites. Nat. Commun. 2015, 6:7289.
50. Hendriks I.A., et al. SUMO-2 orchestrates chromatin modifiers in response to DNA damage. Cell Rep. 2015, 10:1778-1791.
51. Olsen J.V., Mann M. Status of large-scale analysis of post-translational modifications by mass spectrometry. Mol. Cell. Proteomics 2013, 12:3444-3452.
52. Tammsalu T., et al. Proteome-wide identification of SUMO2 modification sites. Sci. Signal. 2014, 7:rs2.
53. Bellail A.C., et al. SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. Nat. Commun. 2014, 5:4234.
54. Bonne-Andrea C., et al. SUMO2/3 modification of cyclin E contributes to the control of replication origin firing. Nat. Commun. 2013, 4:1850.
55. Cubenas-Potts C., et al. Identification of SUMO-2/3-modified proteins associated with mitotic chromosomes. Proteomics 2015, 15:763-772.
56. Jentsch S., Psakhye I. Control of nuclear activities by substrate-selective and protein-group SUMOylation. Annu. Rev. Genet. 2013, 47:167-186.
57. Mukhopadhyay D., et al. The SUMO protease SENP6 is essential for inner kinetochore assembly. J. Cell Biol. 2010, 188:681-692.
58. Yang F., et al. BubR1 is modified by sumoylation during mitotic progression. J. Biol. Chem. 2012, 287:4875-4882.
59. Ban R., et al. Mitotic kinase Aurora-B is regulated by SUMO-2/3 conjugation/deconjugation during mitosis. Genes Cells 2011, 16:652-669.
60. Montpetit B., et al. Sumoylation of the budding yeast kinetochore protein Ndc10 is required for Ndc10 spindle localization and regulation of anaphase spindle elongation. J. Cell Biol. 2006, 174:653-663.
61. Fernandez-Miranda G., et al. SUMOylation modulates the function of Aurora-B kinase. J. Cell Sci. 2010, 123:2823-2833.
62. D'Ambrosio L.M., Lavoie B.D. Pds5 prevents the PolySUMO-dependent separation of sister chromatids. Curr. Biol. 2014, 24:361-371.
63. Mo Y.Y., et al. A role for Ubc9 in tumorigenesis. Oncogene 2005, 24:2677-2683.
64. Moschos S.J., et al. Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Hum. Pathol. 2010, 41:1286-1298.
65. Zhu S., et al. Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene 2010, 29:1763-1772.
66. Wang C., et al. Tumor-suppressive microRNA-145 induces growth arrest by targeting SENP1 in human prostate cancer cells. Cancer Sci. 2015, 106:375-382.
67. Wang K., Zhang X.C. Inhibition of SENP5 suppresses cell growth and promotes apoptosis in osteosarcoma cells. Exp. Ther. Med. 2014, 7:1691-1695.
68. He X., et al. Characterization of the loss of SUMO pathway function on cancer cells and tumor proliferation. PLoS ONE 2015, 10:e0123882.
69. Kessler J.D., et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012, 335:348-353.
70. Beroukhim R., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
71. Sabo A., et al. SUMOylation of Myc-family proteins. PLoS ONE 2014, 9:e91072.
72. Kalkat M., et al. Identification of c-MYC SUMOylation by mass spectrometry. PLoS ONE 2014, 9:e115337.
73. Gonzalez-Prieto R., et al. c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4. Cell Cycle 2015, 14:1859-1872.
74. Evan G. Cancer. Taking a back door to target Myc. Science 2012, 335:293-294.
75. Wierstra I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv. Cancer Res. 2013, 119:191-419.
76. Myatt S.S., et al. SUMOylation inhibits FOXM1 activity and delays mitotic transition. Oncogene 2013, 33:4316-4329.
77. Zhang J., et al. Polo-like Kinase 1-mediated phosphorylation of forkhead box protein M1b antagonizes Its SUMOylation and facilitates its mitotic function. J. Biol. Chem. 2015, 290:3708-3719.
78. Shao D.F., et al. High-level SAE2 promotes malignant phenotype and predicts outcome in gastric cancer. Am. J. Cancer Res. 2015, 5:140-154.
79. Bertolotto C., et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011, 480:94-98.
80. Yokoyama S., et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011, 480:99-103.
81. De T.H., et al. The cell biology of disease: acute promyelocytic leukemia, arsenic, and PML bodies. J. Cell Biol. 2012, 198:11-21.
82. Zhu J., et al. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 2005, 7:143-153.
83. Gostissa M., et al. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 1999, 18:6462-6471.
84. Muller S., et al. c-Jun and p53 activity is modulated by SUMO-1 modification. J. Biol. Chem. 2000, 275:13321-13329.
85. Roukens M.G., et al. Identification of a new site of sumoylation on Tel (ETV6) uncovers a PIAS-dependent mode of regulating Tel function. Mol. Cell Biol. 2008, 28:2342-2357.
86. Comerford K.M., et al. Small ubiquitin-related modifier-1 modification mediates resolution of CREB-dependent responses to hypoxia. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:986-991.
87. Becker J., et al. Detecting endogenous SUMO targets in mammalian cells and tissues. Nat. Struct. Mol. Biol. 2013, 20:525-531.
88. Fukuda I., et al. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem. Biol. 2009, 16:133-140.
89. Licciardello M.P., et al. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation. Oncogene 2014, 34:3780-3790.
90. Bossis G., Melchior F. Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes. Mol. Cell 2006, 21:349-357.
91. Bossis G., et al. The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs. Cell Rep. 2014, 7:1815-1823.
92. Zhao B., et al. SUMO-mimicking peptides inhibiting protein SUMOylation. Chembiochem 2014, 15:2662-2666.
93. Lallemand-Breitenbach V., et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 2008, 10:547-555.
94. Tatham M.H., et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 2008, 10:538-546.
95. Zhang X.W., et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010, 328:240-243.
96. Weisshaar S.R., et al. Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML. FEBS Lett. 2008, 582:3174-3178.
97. Cheng J., et al. SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 2007, 131:584-595.
98. Keith B., et al. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2012, 12:9-22.
99. Xu J., et al. SENP1 inhibition induces apoptosis and growth arrest of multiple myeloma cells through modulation of NF-kappaB signaling. Biochem. Biophys. Res. Commun. 2015, 460:409-415.
100. Kumar A., Zhang K.Y. Advances in the development of SUMO specific protease (SENP) inhibitors. Comput. Struct. Biotechnol. J. 2015, 13:204-211.
101. Bawa-Khalfe T., Yeh E.T. SUMO losing balance: SUMO proteases disrupt SUMO homeostasis to facilitate cancer development and progression. Genes Cancer 2010, 1:748-752.
102. Hsieh Y.L., et al. Ubc9 acetylation modulates distinct SUMO target modification and hypoxia response. EMBO J. 2013, 32:791-804.
103. Demarque M.D., et al. Sumoylation by Ubc9 regulates the stem cell compartment and structure and function of the intestinal epithelium in mice. Gastroenterology 2011, 140:286-296.
104. Soucy T.A., et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009, 458:732-736.
105. Guo W.H., et al. Overexpression of SUMO-1 in hepatocellular carcinoma: a latent target for diagnosis and therapy of hepatoma. J. Cancer Res. Clin. Oncol. 2011, 137:533-541.
106. Zhang H., et al. Over-expression of small ubiquitin-related modifier-1 and sumoylated p53 in colon cancer. Cell Biochem. Biophys. 2013, 67:1081-1087.
107. Oliveira Alves M.G., et al. Study of MDM2 and SUMO-1 expression in actinic cheilitis and lip cancer. Arch. Dermatol. Res. 2014, 306:837-841.
108. Mei D., et al. Up-regulation of SUMO1 pseudogene 3 (SUMO1P3) in gastric cancer and its clinical association. Med. Oncol. 2013, 30:709.
109. Shao D.F., et al. High-level SAE2 promotes malignant phenotype and predicts outcome in gastric cancer. Am. J. Cancer Res. 2015, 5:589-602.
110. Liu X., et al. Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer. J. Hematol. Oncol. 2015, 8:67.
111. Li H., et al. Ubc9 promotes invasion and metastasis of lung cancer cells. Oncol. Rep. 2013, 29:1588-1594.
112. Wozniak K., et al. Polymorphism of UBC9 gene encoding the SUMO-E2-conjugating enzyme and breast cancer risk. Pathol. Oncol. Res. 2013, 20:67-72.
113. Chen S.F., et al. Ubc9 expression predicts chemoresistance in breast cancer. Chin J. Cancer 2011, 30:638-644.
114. Driscoll J.J., et al. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood 2010, 115:2827-2834.
115. Yang W., et al. Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival. Cancer Sci. 2013, 104:70-77.
116. Hoefer J., et al. PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am. J. Pathol. 2012, 180:2097-2107.
117. Toropainen S., et al. SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin. Nucleic Acids Res. 2015, 43:848-861.
118. Wang L., Banerjee S. Differential PIAS3 expression in human malignancy. Oncol. Rep. 2004, 11:1319-1324.
119. Liu B., et al. PIAS1 regulates breast tumorigenesis through selective epigenetic gene silencing. PLoS ONE 2014, 9:e89464.
120. Li J., et al. PIAS3, an inhibitor of STAT3, has intensively negative association with the survival of gastric cancer. Int. J. Clin. Exp. Med. 2015, 8:682-689.
121. Sun L., et al. PIASy mediates hypoxia-induced SIRT1 transcriptional repression and epithelial-to-mesenchymal transition in ovarian cancer cells. J. Cell Sci. 2013, 126:3939-3947.
122. Chien W., et al. PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells. Br. J. Cancer 2013, 109:1795-1804.
123. Horio Y., et al. Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines. Cancer Chemother. Pharmacol. 2010, 66:237-243.
124. Lim J.H., et al. RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia. Cancer Genet. 2014, 207:40-45.
125. Bawa-Khalfe T., et al. SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J. Biol. Chem. 2010, 285:25859-25866.
126. Wang Q., et al. SUMO-specific protease 1 promotes prostate cancer progression and metastasis. Oncogene 2013, 32:2493-2498.
127. Xu Y., et al. SUMO-specific protease 1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CDK inhibitors. Cancer Lett. 2011, 309:78-84.
128. Han Y., et al. SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress. J. Biol. Chem. 2010, 285:12906-12915.
129. Shen H.J., et al. SENP2 regulates hepatocellular carcinoma cell growth by modulating the stability of beta-catenin. Asian Pac. J. Cancer Prev. 2012, 13:3583-3587.
130. Qian J., et al. Inhibition of SENP6-induced radiosensitization of human hepatocellular carcinoma cells by blocking radiation-induced NF-kappaB activation. Cancer Biother. Radiopharm. 2013, 28:196-200.
131. Tan M.Y., et al. SUMO-Specific protease 2 suppresses cell migration and invasion through inhibiting the expression of MMP13 in bladder cancer cells. Cell. Physiol. Biochem. 2013, 32:542-548.
132. Ren Y.H., et al. De-SUMOylation of FOXC2 by SENP3 promotes the epithelial-mesenchymal transition in gastric cancer cells. Oncotarget 2014, 5:7093-7104.
133. Sun Z., et al. Overexpression of SENP3 in oral squamous cell carcinoma and its association with differentiation. Oncol. Rep. 2013, 29:1701-1706.
134. Cheng Y., et al. Sentrin/small ubiquitin-like modifier-specific protease 5 protects oral cancer cells from oxidative stress-induced apoptosis. Mol. Med. Rep. 2015, 12:2009-2014.
135. Ding X., et al. Overexpression of SENP5 in oral squamous cell carcinoma and its association with differentiation. Oncol. Rep. 2008, 20:1041-1045.
136. Cashman R., et al. SENP5 mediates breast cancer invasion via a TGFbetaRI SUMOylation cascade. Oncotarget 2014, 5:1071-1082.
137. Mooney S.M., et al. Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential. Biochemistry 2010, 49:1-10.
138. Bermejo J.L., et al. Exploring the association between genetic variation in the SUMO isopeptidase gene USPL1 and breast cancer through integration of data from the population-based GENICA study and external genetic databases. Int. J. Cancer 2013, 133:362-372.
139. Bachant J., et al. The SUMO-1 isopeptidase Smt4 is linked to centromeric cohesion through SUMO-1 modification of DNA topoisomerase II. Mol. Cell 2002, 9:1169-1182.
140. Ryu H., et al. PIASy-dependent SUMOylation regulates DNA topoisomerase IIalpha activity. J. Cell Biol. 2010, 191:783-794.
141. Ryu H., Azuma Y. Rod/Zw10 complex is required for PIASy-dependent centromeric SUMOylation. J. Biol. Chem. 2010, 285:32576-32585.
142. Sridharan V., et al. SUMOylation regulates Polo-like kinase 1-interacting checkpoint helicase (PICH) during mitosis. J. Biol. Chem. 2015, 290:3269-3276.
143. Ryu H., et al. PIASy mediates SUMO-2/3 conjugation of poly(ADP-ribose) polymerase 1 (PARP1) on mitotic chromosomes. J. Biol. Chem. 2010, 285:14415-14423.
144. Desterro J.M., et al. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol. Cell 1998, 2:233-239.